Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3619298 | 0.94 | CA1 (0.60) | CTSKEPHX1HSD11B1CYP2C9BTK | |
| SCHEMBL4044287 | 0.90 | CTSK (0.61) | CTSKEPHX1HSD11B1CYP2C9BTK | |
| SCHEMBL2049277 | 0.90 | CTSK (0.61) | CTSKEPHX1HSD11B1CYP2C9BTK | |
| SCHEMBL4042455 | 0.90 | CTSK (0.61) | CTSKEPHX1HSD11B1CYP2C9BTK | |
| SCHEMBL2692802 | 0.89 | CTSK (0.55) | CTSKEPHX1HSD11B1CYP2C9BTK | |
| SCHEMBL89460 | 0.87 | EPHX2 (0.56) | CTSKEPHX1HSD11B1CYP2C9BTK | |
| SCHEMBL18926997 | 0.87 | EPHX1 (0.70) | CTSKEPHX1HSD11B1CYP2C9BTK | |
| SCHEMBL27408850 | 0.87 | CTSK (0.56) | CTSKEPHX1HSD11B1CYP2C9BTK | |
| SCHEMBL20495238 | 0.86 | CTSK (0.53) | CTSKEPHX1HSD11B1CYP2C9BTK | |
| SCHEMBL19024479 | 0.86 | HSD11B1 (0.54) | CTSKEPHX1HSD11B1CYP2C9BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0886637-B9 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-05-04 | — | — | EP | claimed |
| EP-0886637-B1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2004-12-01 | — | — | EP | claimed |
| EP-0886637-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0886637-A4 | — | — | 1998-12-30 | — | — | EP | claimed |
| WO-1996026205-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-29 | — | — | WO | claimed |
| WO-2024152247-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS , INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024054625-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-20150307475-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| CN-103068797-B | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | SANOFI SA | 2015-03-11 | — | — | CN | disclosed |
| EP-0886637-B9 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0886637-B1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6066650-A | USEFUL FOR LOWERING SERUM LIPIDS AND TREATING ATHEROSCLEROSIS AND RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-23 | — | — | US | disclosed |
| US-6034098-A | ATHEROSCLEROSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0886637-A4 | — | — | 1998-12-30 | — | — | EP | disclosed |
| EP-0886637-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1996026205-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307475-A1 | Autotaxin inhibitors | ENPP2, ATXN10, ATXN2L | CTSK 180/4885EPHX1 1257/4885HSD11B1 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.